For those of you who would like to take advantage of our Luck O' the Irish SALE but prefer not to make payments online, you are welcome to send us a check or money order in the amount of $114.12 for a 3-year AD-FREE Premium Service Bundle or $190.20 for a 5-year Bundle. Make checks or money orders payable in US funds to "Investor Village" and send to: Investor Village, P.O. Box 2958, Marrero, LA 70073.
As many of you know, we operate on the honor system around here. So, in closing out our Luck O' the Irish SALE, we wanted to advise those of you who plan to pay by check or money order that you can send a PM to Admin informing us of your intention. We will then upgrade your account for 7 days, allowing you to enjoy our ad-free premium service now and giving you a reasonable amount of time to get your payment in.
For example, Ionis Pharmaceuticals (IONS) is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases.
Themes: Ionis is exposed to medicine and neuroscience, nano technology, and big data and analytics.
Fair Value Estimate: We assign Ionis a fair value of estimate of $62 per share, implying a 2021 enterprise value/sales multiple of 12 times.
Growth Forecast: Ionis relies on up-front payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its pipeline should help diversify revenue by the mid-2020s. In our base case, we assume Ionis sees revenue growing to $3.1 billion by 2030 from under $1.0 billion last year, with operating margins approaching 50%.
Morningstar Economic Moat Rating: We assign Ionis a narrow economic moat based on its proprietary antisense oligonucleotide technology, which has led to three approved RNA-based drugs and a steadily growing pipeline.